Skip to Content

Pegaptanib Ophthalmic Dosage

Applies to the following strength(s): 0.3 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Macular Degeneration

Neovascular (wet) age-related macular degeneration: 0.3 mg by intravitreous injection into the affected eye once every 6 weeks.

The procedure should be carried out under controlled aseptic conditions. Anesthesia and a broad-spectrum microbicide should be administered before the injection.

Renal Dose Adjustments

No adjustments recommended

Liver Dose Adjustments

Data not available


Pegaptanib is only indicated for ophthalmic intravitreous injection. It is contraindicated in patients with ocular or periocular infections.

Proper aseptic injection technique should be used when administering pegaptanib.
Intraocular pressure and perfusion of the optic nerve should be monitored after injection and appropriately managed.

It is recommended to review the patient's medical history for hypersensitivity reactions prior to initiating the procedure. There are rare reports of anaphylaxis/anaphylactoid reactions following administration of pegaptanib ophthalmic.

Safety and efficacy have not been established in pediatric patients (less than 18 years of age).


Data not available

Other Comments

There are no data on the safety and efficacy of concurrent administration to both eyes or of treatment duration greater than 2 years.